MLAB · Mesa Laboratories Inc /Co/
$124.76
+5.61 (+4.71%)
At close · Aug 21
View the 10-K filed Jun 3, 2026
Customer concentration
— top customer 20% of revenue
One customer — 20% of revenue (fiscal 2026)
“In our Clinical Genomics division, a significant portion of revenues is generated from ongoing purchases by a relatively small number of established customers, with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026.”
Market Cap
$698.14M
Shares
5.60M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$124.76
Open$119.94
Day$119.03–124.89
52W close$59.53–124.76
Avg vol 30d159K
Short int324K · 5.8% float · 2.5d
Short vol48%
Last earningsAug 10, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 10
Up next
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+36%
above
Price vs 50-day avg
+23%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+28%
trailing
6-month return
+34%
trailing
YTD return
+59%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $102 › 200d $92 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +20 funds added
Insider flow
Distributing
Net -$415.4K over 90 days · 67% sells
Short interest
Rising
5.79% of float · ▲ +18.2% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
156 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
Gross margin
165%
expanding
EPS growth
+436%
Y/Y
Free cash flow
$39.6M
Valuation
P/E 146.8
rich
Balance sheet
$4.2M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+36%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $102 › 200d $92 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +20 funds added
Insider flow
Distributing
Net -$415.4K over 90 days · 67% sells
Short interest
Rising
5.79% of float · ▲ +18.2% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
156 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $60
Now $125 · 100%
Range high $125
vs 200-day avg +36%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AOI (non-GAAP) non-GAAP | $15.04M | Q1 FY2027 | — |
|
|
|||
| AOI excluding unusual items per share – basic (non -GAAP) non-GAAP | $2.73 | Three Months Ended June 30, 2026 | — |
| AOI excluding unusual items per share – diluted (non-GAAP) non-GAAP | $2.68 | Q1 FY2027 | — |
|
|
|||
| AOI growth non-GAAP | 16.5% | Q1 FY2027 | — |
|
|
|||
| AOI per share - basic (non-GAAP) non-GAAP | $2.66 | Three Months Ended June 30, 2026 | — |
| AOI per share - diluted (non-GAAP) non-GAAP | $2.61 | Q1 FY2027 | — |
|
|
|||
| BPD revenues | $12.06M | Q1 FY2027 | +5.0% |
|
|
|||
| CG core organic revenues growth non-GAAP | -1.1% | Q1 FY2027 | — |
| CG revenues | $10.29M | Q1 FY2027 | -0.1% |
|
|
|||
| Core organic revenues growth non-GAAP | 0.4% | Q1 FY2027 | — |
|
|
|||
| CS revenues | $13.29M | Q1 FY2027 | +7.6% |
|
|
|||
| Non-GAAP adjusted operating income (AOI) excluding unusual items non-GAAP | $15.42M | Q1 FY2027 | — |
|
|
|||
| Non-GAAP organic revenues growth non-GAAP | 1% | Q1 FY2027 | — |
| Organic revenues growth (non-GAAP) non-GAAP | 1% | Three Months Ended June 30, 2026 | — |
| SDC core organic revenues growth non-GAAP | -4.6% | Q1 FY2027 | — |
| SDC revenues | $24.51M | Q1 FY2027 | -3.6% |
|
|
|||
| Total Net Leverage Ratio non-GAAP | 1.85 | Q1 FY2027 | — |
|
|
|||
| AOI excluding unusual items (non-GAAP) non-GAAP | 63.49M | Year Ended March 31, 2026 | — |
|
|
|||
| Free cash flow non-GAAP | 39.58M | FY2026 | — |
| Organic revenues growth non-GAAP | 3.7% | Nine Months Ended December 31, 2025 | — |
| Organic revenues growth excluding CG China revenues non-GAAP | 6.6% | Nine Months Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Scientific & Technical Instruments — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLAB
this stock
Mesa Laboratories Inc /Co/
|
$698.14M | +58.9% | +2.7% | 146.8 | 5.8% |
|
GRMN
Garmin Ltd
|
$56.74B | +45.4% | +15.1% | 32.8 | 1.9% |
|
COHR
Coherent Corp.
|
$56.70B | +56.9% | +19.2% | 70.3 | 4.6% |
|
KEYS
Keysight Technologies, Inc.
|
$54.12B | +55.6% | +8.0% | 51.9 | 1.9% |
|
TDY
Teledyne Technologies Inc
|
$29.49B | +24.6% | -4.6% | 30.8 | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLAB | +17.7% | +28.0% | +33.8% | +23.8% | +58.9% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +19.0% | +24.3% | +22.3% | +21.3% | +46.6% |
Capital returns
Latest dividend
$0.16
/ share · ex May 29, 2026
Declared · upcoming
$0.16
/ share · ex Aug 31, 2026
Paid (TTM)
$0.64
/ share · 4 payouts
Dividend yield (TTM, derived)
0.51%
Buyback program
· as of Nov 30, 2005
Authorized
shares 300,000
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.